MediPharm Labs Third Quarter Financial Report Announcement
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) is delighted to announce a significant upcoming event in its financial calendar. The company, renowned for its precision-based cannabinoids products, will reveal its financial results for the third quarter of 2025. This report will cover the three and nine months that concluded on September 30, 2025, and will be made public before the market opens on Thursday, November 13, 2025.
Details of the Earnings Call
In conjunction with its financial report, MediPharm Labs will organize a conference call and webcast on the same day, allowing stakeholders to engage directly with the executive management team. The call is scheduled for 10:00 a.m. Eastern time. It provides an excellent opportunity for analysts, investors, and other interested parties to understand the company’s financial health and strategic direction moving forward.
Participation Information
Participants wishing to join the conference call can do so using the following details:
- North America Toll-Free: (888) 330-2454
- International Toll: +1 (240) 789-2714
- Conference ID: 4921762
It’s recommended that participants join approximately 15 minutes prior to the start to ensure a smooth experience. For those unable to attend the live session, a replay will be accessible the next day through the company’s investor webpage.
About MediPharm Labs
Founded in 2015, MediPharm Labs has carved a niche in the pharmaceutical industry by excelling in the development and manufacturing of high-quality cannabis extracts and cannabinoid products. The company operates in a facility that adheres to Good Manufacturing Practices (GMP) standards, ensuring that its end products are both safe and effective for consumers. MediPharm Labs has a strong commitment to research and innovation, which is evident in its advanced manufacturing processes and precise dosing techniques.
Regulatory Milestones and Expansion
In a major breakthrough, MediPharm Labs secured a Pharmaceutical Drug Establishment License from Health Canada, distinguishing itself as the only North American company with a GMP License for extracting multiple natural cannabinoids on a commercial scale. This pivotal license enhances MediPharm’s credibility and positions it favorably for international market expansion.
Further extending its market reach, MediPharm Labs acquired VIVO Cannabis Inc., which allowed it to serve medical patients across Canada more effectively. This acquisition also integrated a medical cannabis platform with comprehensive patient support through Canna Farms, further supporting patient education and access to quality cannabis products.
Frequently Asked Questions
What is the main focus of MediPharm Labs?
MediPharm Labs specializes in the development and manufacture of high-quality cannabis concentrates and cannabinoid products.
When will MediPharm Labs announce their third quarter financial results?
The financial results will be announced before markets open on Thursday, November 13, 2025.
How can investors participate in the earnings call?
Investors can join the conference call by dialing in with the provided North America toll-free or international numbers.
What significant licenses has MediPharm Labs obtained?
MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, enabling it to produce cannabinoids at a commercial scale.
What recent acquisitions has MediPharm Labs made?
MediPharm Labs recently acquired VIVO Cannabis Inc., which expanded its medical patient reach across Canada and into new international markets.
